Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Mar 2;14(1):249-255.
doi: 10.1159/000511396. eCollection 2021 Jan-Apr.

Idiopathic Hypereosinophilic Syndrome with Multiple Organ Involvement

Reham Abo Shdid  1 , Bahjat Azrieh  1 , Seham Alebbi  1 , Shafik Mansour  1 , Muhammad Naeem  2
Affiliations
Case Reports

Idiopathic Hypereosinophilic Syndrome with Multiple Organ Involvement

Reham Abo Shdid et al. Case Rep Oncol. .

Abstract

Idiopathic hypereosinophilic syndrome is a rare disease which is diagnosed after excluding other conditions. The syndrome is characterized by multiple organ involvement including the heart, nervous system, lungs, and gastrointestinal tract. The disease is suspected if there is peripheral blood eosinophilia and no clear etiology. The main treatment is corticosteroids. Patients who do not respond to corticosteroids can be treated with imatinib, immunomodulatory agents, myelosuppressive therapy, or mepolizumab. Alemtuzumab can be considered in severe cases that are unresponsive to other therapies. In this paper, we describe a case of idiopathic hypereosinophilic syndrome with mainly cardiac system involvement and left ventricular thrombus formation which was complicated by cerebral thromboemboli while on warfarin with international normalized ratio in the therapeutic range. Our patient responded well to steroids appreciated by improvement in clinical symptoms and decrease in eosinophil count.

Keywords: Eosinophilia; Hypereosinophilic syndrome; Idiopathic hypereosinophilic syndrome; Multiple organ involvement.

PubMed Disclaimer

Conflict of interest statement

The authors have nothing to disclose.

References

    1. Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the litarature. Medicine. 1975;54((1)):1–27. - PubMed
    1. Simon HU, Rothenberg ME, Bochner BS, Weller PF, Wardlaw AJ, Wechsler ME, et al. Refining the definition of hypereosinophilic syndrome. J Allergy Clin Immunol. 2010;126((1)):45–9. - PMC - PubMed
    1. Klion AD. Eosinophilia: a pragmatic approach to diagnosis and treatment. Hematology Am Soc Hematol Educ Program. 2015;2015:92–7. - PubMed
    1. Valent P, Klion AD, Horny HP, Roufosse F, Gotlib J, Weller PF, et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol. 2012;130((3)):607–612.e9. - PMC - PubMed
    1. Kleinfeldt T, Nienaber CA, Kische S, Akin I, Turan RG, Körber T, et al. Cardiac manifestation of the hypereosinophilic syndrome: new insights. Clin Res Cardiol. 2010;99((7)):419–27. - PubMed

Publication types

LinkOut - more resources